Pulmo BioTech Inc. Reveals Its PulmoBind(TM) Pulmonary Vascular Diagnostic Product Candidate May Apply to Early Stage Diagnosis
June 07 2010 - 9:00AM
"Pulmo BioTech Inc. (OTCBB:PLMO) (Frankfurt:PBO) has announced that
early indications are that its PulmoBind™ product candidate has the
potential for early diagnosis of Pulmonary Hypertension (PH) in the
pediatric population. PH is a potentially life threatening and
crippling disease; it is also very hard to diagnose. A typical
diagnostic path for PH would include 2D Echocardiography with
Doppler Flow studies, High Res CT of the chest, VP Lung Scanning
and Cardiac Catheterization. Such diagnostic studies are expensive
and in the case of Cardiac Catheterization, highly invasive. It is
difficult to justify exposing infants to such a battery of tests
without high prior clinical suspicion of PH and therefore justifies
the need for simpler and possibly earlier diagnostic modalities. If
our early experimental results are borne out by further experiments
and trials, then PulmoBind™, as a simple, non-invasive screening
test could be of particular benefit to the diagnosis of PH and
other conditions afflicting the Pulmonary Vascular system in
pediatric subjects where early stage diagnosis is perhaps of even
more importance than it is in adults," stated Garry McCann,
CEO Pulmo BioTech Inc.
About Pulmo BioTech Inc.
Pulmo BioTech Inc. specializes in the development and marketing
of medical technology and research. Our proven strengths combine
extensive commercial experience and academic credentials. The
principal staff members are acknowledged experts in their
specialized fields, and work with a broad range of investment
institutions. Our mission is to utilize scientific imagination and
drive, together with managerial and financial acumen, to bring
innovative and profitable products to the marketplace to the
benefit of all stockholders.
ISIN: US7458451074
CUSIP: 745845107
WKN: A0RDTZ
About PulmoScience Inc.
PulmoScience Inc. was established in 2006, and is currently
developing a non-invasive Molecular Imaging technique for the
diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung
Inflammatory diseases under the trade name
PulmoBind™.
PulmoScience was conceived within the Montreal Heart Institute
"MHI" (a world renowned hospital and educational facility). Jointly
owned by MHI subsidiary Innovacor as the technical and operational
partner, Dr. Jocelyn Dupuis (the scientific director and originator
of the PulmoBind™ Molecular Imaging technology), and by Pulmo
BioTech Inc. as the funding partner, PulmoScience Inc. aims to
develop this unique and exciting technology, to fund necessary
trials, and to bring the products to market.
PulmoScience believes that the market for its product candidates
is worth in excess of $500 million per annum and that, provided
Regulatory Approval is achieved, the safety and efficacy of its
products could allow it to dominate that market.
About PulmoBind™
PulmoBind™ uses an intravenously delivered radionuclide tagged
molecule which specifically bonds to the inner walls of the
circulatory system in the lungs, and by the use of an external
Gamma Camera allows an image of the integrity of the blood vessels
throughout the lungs to be seen by a diagnostic clinician.
PulmoScience is currently undertaking Regulatory Approval for Phase
I Human Trials, and while subsequent results from additional tests
might not corroborate the current results, PulmoScience believes
that PulmoBind™ has the potential to dominate the market for the
diagnosis of Pulmonary Embolism. In particular, this belief
is driven by PulmoScience's expectations of the improved safety and
efficacy that PulmoBind™ will offer when compared to the current
incumbent nuclear medicine based technology for the diagnosis of
Pulmonary Embolism. In addition, early indications are that
PulmoBind™ could be highly effective in the early stage diagnosis
of Pulmonary Hypertension, a condition for which there is no
current front line diagnostic test. The addressable market for the
product candidates being developed by PulmoScience is believed by
the company to be worth in excess of $500 million per annum.
Further Information
For further information regarding Pulmo BioTech Inc. or
PulmoScience, please visit
www.pulmobiotech.com
Forward-Looking Statements
Forward-looking statements contained in this and other written
and oral reports are made based on known events and circumstances
at the time of release, and as such, are subject in the future to
unforeseen uncertainties and risks. All statements regarding future
performance, earnings projections, regulatory approval, events or
developments are forward-looking statements. It is possible that
the future performance of the company may differ materially from
current expectations, depending on economic conditions and the
uncertainty of regulatory approval. A change in economic conditions
may have a particularly volatile effect on results. Among the other
factors which may affect future performance are: competitive market
conditions and resulting effects on sales and pricing; increases in
raw-material costs that cannot be recovered in product pricing; and
global economic factors, including difficulties entering new
markets and general economic conditions such as inflation, interest
rates and credit availability. The company makes these statements
as of the date of this disclosure, and undertakes no obligation to
update them.
CONTACT: Pulmo BioTech Inc.
Peter B. Hirshfield
+1-646-827-9362
phirshfield@hirshfieldlaw.com